Open AccessA comparison of six fractions per week chemoradiation versus five fractions per week of conventional chemoradiation in carcinoma cervix: A prospective controlled study
Author(s) -
Deepak Kumar,
Satyajit Pradhan,
Sunil Choudhary,
Lalit Mohan Aggarwal,
Avipsa Das,
Sovan Sarangdhar,
Prashant Kaser,
Satish Dewangan
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_698_19
Subject(s) - medicine , cervix , cisplatin , brachytherapy , chemoradiotherapy , radiation therapy , clinical endpoint , stage (stratigraphy) , carcinoma , prospective cohort study , surgery , urology , randomized controlled trial , gastroenterology , chemotherapy , nuclear medicine , cancer , biology , paleontology
The standard of care for carcinoma cervix stage IB2-IVA is five fractions per week of radiotherapy (RT) with concurrent cisplatin. We compared the standard treatment with six fractions per week of RT with concurrent Cisplatin to see whether the later had improved survival outcomes with comparable toxicities.